Prodia (PRDA IJ) - Shaking off the COVID Factor
Prodia (PRDA IJ) stands out as the unique diagnostic leader in Indonesia, which trades at a significant discount to both local healthcare players...
686 Views
Prodia (PRDA IJ) - Back to Core Testing
Prodia (PRDA IJ) FY2022 results saw declines in revenues and profits but from a COVID-high base and the numbers are now well-above 2019, with...
700 Views
Dr Lal PathLabs (DLPL IN): Losing Path Amid Competition; Non-COVID Growth Underwhelming
India diagnostic sector is overcrowded, leading to price competition and declining realization per test. Currently, DLPL’s three-year patient...
663 Views
India: AMFI Stock Reclassification Preview (June 2023)
Nearly halfway through the review period, we see 10 stocks moving from MidCap to LargeCap and vice versa, 9 from SmallCap to MidCap and vice versa....
540 Views
Prodia (PRDA IJ): Digital Initiative Cannot Be a Game Changer in Near-Term
Prodia launched a new digital healthcare platform to augment its growth amid the absence of COVID-related windfall gain. However, this initiative...
513 Views